Difei Yang
Stock Analyst at Mizuho
(1.89)
# 2,831
Out of 4,818 analysts
36
Total ratings
28.12%
Success rate
4.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $2.28 | -12.28% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $580 → $460 | $4.16 | +10,957.69% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $18.55 | +978.17% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $2.02 | +1,785.86% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.32 | +8,962.50% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $14.26 | +264.66% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $61.76 | +159.07% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $4.28 | +227.10% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $0.74 | +4,640.62% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.54 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $9.20 | +204.35% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.27 | +1,133.48% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $2.28
Upside: -12.28%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $580 → $460
Current: $4.16
Upside: +10,957.69%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $18.55
Upside: +978.17%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $2.02
Upside: +1,785.86%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.32
Upside: +8,962.50%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $14.26
Upside: +264.66%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $61.76
Upside: +159.07%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $4.28
Upside: +227.10%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $0.74
Upside: +4,640.62%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.54
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $9.20
Upside: +204.35%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $2.27
Upside: +1,133.48%